Exploring anti-VEGF therapy for wet AMD: What dosing strategy is best?

Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney
February 2011
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p22
Academic Journal
The article offers insights from doctor Philip J. Rosenfeld regarding the best dosing strategy for studying anti-vascular endothelial growth factors (VEGF) therapy for wet age-related macular degeneration (AMD).


Related Articles

  • Anti-VEGF maintains visual acuity gains at 1 year in patients with neovascular AMD. Hasson, Matt; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p31 

    The article reports on the study which found that pegatinib, an induction-maintenance therapy, can improve visual acuity and stabilized center point thickness in patients that have neovascular age-related macular degeneration.

  • Woman complains of gradual decrease in vision. Renz, Jennifer; Duker, Jay S. // Ocular Surgery News;6/10/2014, Vol. 32 Issue 11, p34 

    The article describes the case of a 65 year old woman who complained of gradually decreasing vision and was diagnosed with neovascular age-related macular generation receiving intravitreal ranibuzumab every 5 to 6 weeks for the last 3 years bilaterally. Topics discussed include her ocular...

  • HIGHER-AFFINITY AGENTS: AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Heier, Jeffrey S. // Johns Hopkins Advanced Studies in Ophthalmology;Feb2013, Vol. 10 Issue 1, p43 

    The article presents two studies results based on information collected at different stages of 52 weeks and 96 weeks showing the change in pattern for treatment of the anti-vascular endothelial growth factor (VEGF). It states that the agents were used to treat patients with neo-vascular (wet)...

  • Evidence for anti-VEGF agent risk rates not significant at present. Cimberle, Michela // Ocular Surgery News;8/25/2013, Vol. 31 Issue 16, p22 

    The article reports on the presentation of Doctor Tien Y. Wong during a meeting of the European Society of Ophthalmology in Copenhagen on the need for additional clinical trials to determine the risk of side effects from using anti-vascular endothelial growth factor agents for the treatment of...

  • Anti-VEGF therapy effective in treatment of myopic CNV.  // Ocular Surgery News;6/10/2012, Vol. 30 Issue 11, p18 

    No abstract available.

  • OCT drives anti-VEGF treatment regimen for neovascular AMD. DiPietro, Cheryl; Hasson, Matt // Ocular Surgery News;12/25/2012, Vol. 30 Issue 24, Special section p2 

    The article reports that decisions made regarding appropriate treatment for neovascular age-related macular degeneration and long-term disease surveillance are driven by Optical coherence tomography (OCT) imaging.

  • Monthly anti-VE6F beneficial in treatment of recalcitrant neovascular AMD. Stewart, Michael W. // Ocular Surgery News;5/25/2013, Vol. 31 Issue 10, p25 

    The article discusses research on the effectiveness of monthly anti-vascular endothelial growth factor (VEGF) in the management of recalcitrant neovascular age-related macular degeneration, published in a 2013 issue of the journal "Ophthalmic Surgery, Lasers and Imaging Retina."

  • In the Journals. Fox, Christi; Hasson, Matt // Ocular Surgery News;7/25/2013, Vol. 31 Issue 14, p19 

    This section presents several articles about ophthalmology published in different journals. These include an article about the therapeutic use of intravitreal ranibizumab for treatment of choroidal neovascularization (CNV) caused by adult-onset foveomacular vitelliform dystrophy, another one...

  • Repeated anti-VEGF injections may alter RNFL thickness. Biro, Ashley // Ocular Surgery News;2/10/2013, Vol. 31 Issue 3, p21 

    The article discusses that anti vascular endothelial growth factor (anti-VEGF) injections can alter retinal nerve fiber layer (RNFL) thickness.


Read the Article


Sign out of this library

Other Topics